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Abstract 
In allergies, an unbalanced immune response towards a T helper (Th) 2 pro-
file with high levels of Immunoglobulin (Ig) E is produced. We have demon-
strated that the pre-administration of Enterococcus faecalis CECT7121 pre-
vents the development of allergy in ovalbumin-immunized mice. In this work, 
we evaluated whether this bacterium can also revert an established allergic 
status. Mice were immunized with ovalbumin (OVA) and after that, were in-
oculated with an E. faecalis CECT7121 suspension. In immunized animals, 
serum specific immune response, proliferative activity of memory splenocytes, 
and levels of Th2 cytokines were assessed. The in vivo active cutaneous ana-
phylaxis test was also performed. The treatment with E. faecalis CECT7121 
only increased anti-OVA IgG2a levels. No differences were observed in other 
specific immunological parameters. Probiotic-treatment did not prove to have 
any desensitizing effect on mice. These results, together with those recently 
published, can be concluded that this bacterium would not be appropriate for 
the treatment of allergic symptoms. 
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1. Introduction 
In most individuals suffering from allergic diseases, an imbalance of the immune 
response towards a Th2 cytokine profile is observed. This Th2 scenario induces 
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the secretion of high levels of IgE, together with the recruitment of effect or cells 
to the site where the allergic inflammatory response is taking place [1] [2] [3] [4] 
[5]. On the other hand, it is known that in healthy individuals, a Th1 response is 
generated against allergens [6]. According to the hygiene hypothesis [5] [7] [8] 
[9], the exposition to microorganisms during the early stages of life could revert 
this Th2-skewed response, and in turn, it could induce the development of a Th1 
phenotype and stimulate the activity of Treg cells. This observation has led to the 
experimental use of microorganisms to prevent or inhibit allergic diseases, being 
the probiotics, the most promising tool for this purpose [10]. There are promi-
nent studies about probiotic pre-treatment which are successfully employed in 
allergies in different models. One of the beneficial effects that have been reported 
is a reduction in the production of serum-specific IgE in mice [11] [12] [13]. 
Probiotic bacteria can induce immune regulation or immune tolerance in aller-
gic diseases as it had been demonstrated in a β-lactoglobulin-induced intestinal 
anaphylaxis in a murine model of food allergy where the oral administration of 
Clostridium butyricum CGMCC0313-1 ameliorated intestinal anaphylaxis symp-
toms and shifted the immune balance towards Th1 and Treg, with significantly 
increased Foxp3/Rorγt and Foxp3/Gata ratios and a significantly decreased Ga-
ta3/Tbet ratio [14]. Furthermore, there are other studies that show that the pro-
biotic administration induces an improvement on allergic symptoms. Yang et al. 
have observed that the treatment for two weeks with Bifidobacterium infantis 
during OVA sensitization attenuated the serum specific IgE and IgG1 secretion 
as well as reduced Th2-type cytokines in spleen cell supernatants and, after chal-
lenge with OVA, probiotic-treated mice showed lower allergic reaction meas-
ured as diarrhea than sensitized-mice [15]. 
Enterococcus faecalis strains are frequently isolated from food products, and 
certain strains have been used as cheese starter and food products in the market 
worldwide [16]. Moreover, they are also employed as probiotics in many appli-
cations for human and animals [17]. We have previously worked with a nonpa-
thogenic strain, Enterococcus faecalis CECT7121, isolated from natural corn si-
lage [18]. We have evidenced that this strain implants and remains in the intes-
tinal mucosa of BALB/c mice, stimulating the immune system [19] [20]. We 
have also demonstrated the adjuvant effect of E. faecalis CECT7121 and its 
broad pro-Th1 immunomodulatory activity, achieving beneficial effects on dif-
ferent experimental models [19] [21] [22] [23]. 
The immunomodulatory effect of E. faecalis CECT7121 has been demon-
strated in an allergy model induced by the subcutaneous (s.c.) administration of 
Ovalbumin (OVA), where this strain was able to diminish the secretion of spe-
cific IgE and to induce an increase in the levels of specific IgG2a. This probiotic 
also decreased the proliferation of splenocytes and the secretion of Th2 cyto-
kines [23]. In the latter model, we have demonstrated that the previous implan-
tation of E. faecalis CECT7121 in the intestinal mucosa prevents the develop-
ment of the allergic status. In order to perform a more insightful assessment of 
the immunomodulatory capacity of this probiotic, in this work, we evaluated 
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whether this probiotic can also revert an established allergic status. Considering 
that probiotic immunomodulatory capacity is broadly assessed as pre-treatment 
in allergy models, but there is little information about probiotic post-treatment 
in an established allergy model, in this work we evaluated whether E. faecalis 
CECT7121 can also revert an established allergic status. For that reason, 
OVA-sensitized mice were treated with the probiotic by the intragastric (i.g.) 
route, evaluating parameters of the Th-2 biased immune response induced by 
the allergen. 
2. Materials and Methods 
2.1. Mice 
Conventional female BALB/c mice were provided by the School of Veterinary 
Medicine, Universidad de Buenos Aires (Argentina). All animals were housed (n 
= 5 mice/cage) under specific conditions according to the “Guide for the Care 
and Use of Laboratory Animals” (National Research Council of the National 
Academies, USA), with controlled air temperature (20˚C - 22˚C), humidity, and 
12 h light/dark cycles; food and water were provided ad libitum. All mice were 6 
weeks old at the beginning of the experiment. 
All animal experiments were approved by the Instituto de Estudios de la In-
munidad Humoral “Prof. Dr. Ricardo A. Margni” (IDEHU, CONICET-UBA). 
Maximum efforts were undertaken to minimize animal suffering in all proce-
dures. 
2.2. Immunization Protocol with OVA and i.g. Administration of 
Ent. faecalis CECT7121 
Mice were divided in two experimental groups: E. faecalis CECT7121/ OVA (n = 
6), S/OVA (saline) (n = 6). OVA immunization [10 μg OVA and 1 mg Al(OH)3] 
was performed on days 0, 7 and 21 by s.c. injection (0.2 ml) on the back of each 
mouse (Figure 1). An E. faecalis CECT7121 suspension (3 × 108 CFU/ml, pre-
pared as previously described [23] was administrated by the i.g. route (0.2 
ml/mice/day) with a gavage needle on three doses: days 1, 2 and 3; days 13, 14 
and 15 and on days 28, 29 and 30. On day 34, serum samples were obtained and 
mice were euthanized by CO2 or cervical dislocation and spleens removed. 
Another group of mice was subjected to the Active Cutaneous Anaphylaxis Test 
(ACA). Control non-immunized animals were treated with saline instead OVA 
or E. faecalis CECT7121 (n = 3 each). 
2.3. Evaluation of Cell Responses 
Individual spleen cell suspensions of each mice were prepared in RPMI 1640 
medium (Gibco) containing fetal calf serum (Natocor), penicillin (Gibco), 
streptomycin (Gibco), amphotericin B (Gibco), L -glutamine (Gibco) and pyru-
vate (J.T. Baker) as previously described [23]. One hundred microlitres of spleen 
cell suspension (4 × 106 cells/ml) were cultured with 100 μl of ulture medium  
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Figure 1. Immunization protocol. Mice were divided in two experimental groups: 
OVA/E. faecalis CECT7121 and OVA/S (saline). OVA immunization [10 μg OVA and 1 
mg Al(OH)3] was performed on days 0, 7 and 21 with 0.2 ml by s.c. injection (empty ar-
row) and an E. faecalis CECT7121 suspension (3 × 108 CFU/ml) was administrated with a 
gavage needle by the i.g. route (0.2 ml/mice/day) on days 1, 2 and 3; 13, 14 and 15; and on 
days 28, 29 and 30. At final day 34, serum samples and splenocyte were taken, and ACA 
was performed. Control non-immunized animals were treated with saline instead OVA 
or E. faecalis CECT7121. 
 
alone or with 100 μl of OVA (1 mg/ml; Sigma-Aldrich) in quadruplicate at 37˚C 
in presence of 5% CO2. Concanavalin A (10 μg/ml; Vector Labs) was used as 
mitogen. In each experiment, two cell cultures were performed: to assess cell 
proliferation and to determine the cytokine levels in supernatants. After 72 h, 
supernatants were collected and stored at –80˚C until assayed for cytokine levels. 
Proliferative responses were assessed after 96 h of culture by [3H] thymidine 
(Perkin- Elmer) uptake and measured by liquid scintillation (Liquid Scintillation 
Analyzer 1600TR; Packard). Results were expressed as mean counts per minute 
± SEM of quadruplicate cultures. 
2.4. Levels of Cytokines and Allergen-Specific Antibodies 
Commercial kits were employed to determine levels of IL-5, IL-10 (BD Bios-
ciences) and IL-13 (Invitrogen). Specific anti-OVA IgE and IgG antibody levels 
were measured by indirect ELISA in individual serum samples, employing OVA 
as coating antigen at 10 μg/ml in phosphate-buffered saline (PBS). A biotiny-
lated anti-mouse IgE antibody (BD Biosciences) followed by an avidine-HRP 
solution or a HRP-conjugated anti-mouse IgG serum (Cappel) or a 
HRP-conjugated anti-mouse IgG1 or a HRP-conjugated anti-mouse IgG2a sera 
(Bethyl) were used as secondary antibodies [23]. To determine the titre of each 
serum sample, two-fold serial dilutions were performed. All determinations were 
performed in duplicate. Absorbance values were obtained after spectrophotome-
tric reading (450 - 570 nm) in an ELISA plate reader (Multiskan EX; Thermo 
Scientific, USA). Antibody titres were calculated as the EC50 (half maximal) 
value obtained by a four-parameter non-linear regression curve in a log reci-
procal-dilution response curve. 
2.5. Active Cutaneous Anaphylaxis 
Active Cutaneous Anaphylaxis (ACA) was induced by intradermic (i.d.) chal-
lenge with the allergen in E. faecalis CECT7121/OVA, S/OVA. Briefly, an intra-
venous injection of 1% w/v Evans Blue (50 μl) was administered by the tail vein, 
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and ACA was then elicited in the right ear by i.d. inoculation of 50 μl OVA (1 
mg/ml). PBS was inoculated in the left ear of each animal as a control reaction. 
Animals were observed after 30 min. 
2.6. Statistical Analysis 
Two separate immunization schedules were carried out. All values were pre-
sented as means with their standard errors. A linear regression of ELISA absor-
bance values of standards was performed. Student’s t test was employed to de-
termine significance of specific antibodies results. Cell responses and cytokine 
levels were analyzed by the Kruskal-Wallis followed by the Dunns multiple 
comparisons test. In all analysis, GraphPad Prism 5.03 for Windows (GraphPad 
Software, USA) was used. 
3. Results and Discussion 
The aim of this work was to study the effect E. faecalis CECT7121 during the ef-
fector phase of the allergic response. We evaluated whether this strain could also 
revert Th2 parameters of the allergic response in an experimental allergy model 
induced by s.c. OVA administration. The parameters assessed ex vivo were se-
cretion of specific IgE, IgG1, IgG2a antibodies and the Th2 cytokines in spleno-
cyte culture supernatants. In addition, an in vivo of the ACA test was performed. 
The development of the allergic response comprises two phases. The first one, 
or sensitization phase, is that CD4+ T cells become activated and differentiated 
into Th2 IL-4, IL-5 and IL-13-secreting cells. These cytokines would induce the 
secretion of IgE and IgG1 by B cells. Both basophils and mast cells have on the 
cell surface of the high affinity IgE receptor (FcεI), allowing this immunoglobu-
lin to bind to the cell membrane. During a second exposure to the allergen, those 
IgE molecules bound to the FcεI induce the receptor cross-linking leading to cell 
activation and the subsequent degranulation and the release of histamine, which 
is one of the soluble mediators responsible for the appearance of clinical symp-
toms of allergy. Probiotics as lactic acid bacteria have immunomodulating ef-
fects, as a reduction in the production of antigen specific serum IgE production, 
which is affected by IL-4 and IL-5 produced by Th2 cells [11] [12] [13] [24]. 
Moreover, Kalliomaki et al. have demonstrated, in a double-blind randomized 
placebo-controlled trial of prevention of atopic disease, that the administration 
of Lactobacillus rhamnosus GG prenatally to mothers and postnatally for 6 
months to their infants was effective in prevention of early atopic disease in 
children [25]. 
The treatment of allergy employing probiotic microorganisms can be em-
ployed to modulate either the sensitization or the effector phase of the response. 
The immunomodulatory activity of probiotics and the period of time over which 
they have positive effects are highly dependent on the strain under study, but al-
so with the dose, the timing of supplementation and the method of administra-
tion [26] [27] [28]. Previously, our group has demonstrated that the i.g. admin-
istration of Enterococcus faecalis CECT7121, prior to the sensitization induced 
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by the administration of OVA, can prevent the establishment of the allergic re-
sponse [23]. 
In the present work, on day 34 after the first immunization with OVA and E. 
faecalis CECT7121 treatment protocols, Th1 and Th2 parameters of the im-
mune response were assessed. Levels of specific anti-OVA IgE and IgG1 
(Th2-immunoglobulins) and IgG2a (Th1-immunoglobulin) were determined. 
No detectable specific immunoglobulins were found in non-immunized animals 
(treated or not with the probiotic; data not shown). Upon analyzing the Th2 
immunoglobulin IgE, it was found that the levels of this specific anti-OVA iso-
type were not affected by the treatment of animals with the probiotic (Table 1). 
No statistical differences were found in the titres of specific IgG1 between im-
munized control group and those treated with the probiotic (Table 1). Contra-
rily, the levels of specific IgG2a were found to be higher in the group of animals 
immunized with OVA and treated with E. faecalis CECT7121 (Table 1). The 
IgG1/IgG2a ratios, therefore, were found to be significantly different between 
both groups of animals. The decrease in the anti-OVA IgG1/IgG2a ratios ob-
served in the group of animals treated with the bacterium accounted for a rise in 
the levels of specific IgG2a. The latter finding is in line with the pro-Th1 activity 
already reported for E. faecalis CECT7121 [19] [21] [22]. 
After The proliferation rates of splenocytes obtained from both E. faecalis 
CECT7121-treated and untreated control animals did not differ from each other 
after the in vitro stimulation with OVA (Figure 2). Moreover, after stimulation 
with OVA, these splenocytes were able to secrete the Th2-related cytokines IL-5, 
IL-13 and the regulatory IL-10; however, no differences were found between 
animals immunized with OVA and those immunized and treated with E. faecalis 
CECT7121 (Figure 3) which indicates that this bacterium was not able to de-
crease the levels of the cytokines evaluated (Figure 3). These results are in 
 
Table 1. Determination of specific IgE, IgG, IgG1 and IgG2a levels in serum samples by 
ELISA after Ova immunization of naïve BALB/c vs. mice treated ig with E. faecalis 
CECT7121. 
Antibodies Mice Group E. faecalis CECT7121/Ova S/Ova 
anti-Ova IgE 
(OD450nm)  0.553 ± 0.277 0.629 ± 0.367 
anti-Ova IgG 
(titre)  108.988 ± 15.563 93.561 ± 12.610 
anti-Ova IgG1 
(titre)  67.057 ± 31.528 59.452 ± 34.763 
anti-Ova IgG2a 
(titre)  5425 ± 2315* 7835 ± 3709 
anti-Ova 
IgG1/anti-Ova 
IgG2a 
 12.70 ± 4.88* 8.26 ± 4.08 
Antibody titres were defined as the mean inversion of dilution at which the absorbance value is 0.5 of each 
mouse. Data represent means ± SEM (n:12). *P < 0.05, Student’s t-test. 
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Figure 2. Comparative cell responses. On day 34 after first im-
munization, spleen cells of each immunized mouse were isolated 
and incubated with culture medium (RPMI) or OVA. Five mice 
from each group were analyzed in each assay and results ex-
pressed as mean count per minute (cpm). Bars represent results 
of three separate assays. ***P < 0.001, Kruskal-Wallis followed by 
the Dunns multiple comparisons test”. 
 
 
Figure 3. Th2 cytokine production. IL-5, IL-13 and IL-10 levels 
measured by ELISA in splenocytes. IL-5, IL-13 and IL-10 levels 
measured by ELISA in splenocytes culture supernatants after in-
cubation with culture medium (RPMI) or OVA for 72 h. Five 
mice from each group were analyzed in each assay and results 
expressed as pg∙ml−1. Bars represent results from three separate 
assays. **P < 0.01, *P < 0.05, Kruskal-Wallis followed by the 
Dunns multiple comparisons test. 
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(a)                                       (b) 
Figure 4. Active cutaneous anaphylaxis. After the intravenous injection of 1% w/v Evans 
Blue (50 μl) by the tail vein, ACA was induced by intradermic challenge with the allergen 
in OVA-immunized, OVA/E. faecalis CECT7121 and control mice (picture not shown) in 
the right ear by inoculation of 50 µl OVA (1 mg/ml). PBS was inoculated in the right ear 
of each animal as control reaction. Animals were observed after 30 min. a) S/OVA group; 
b) E. faecalis CECT7121/OVA group. Arrows show the inoculation site in immunized 
animals. 
 
agreement with the titres of specific IgE found in allergic animals, since it is 
known that IL-4, IL-5 and IL-13 are the cytokines involved in IgE synthesis reg-
ulation [2] [29] [30]. 
Even though the immunological ex vivo determinations indicated that E. fae-
calis CECT7121 was incapable of reverting the allergic status, the in vivo ACA 
test was performed, since it has been demonstrated that this test can account for 
amelioration of the allergic symptoms, as is the case of the treatment with Lac-
tococcus lactis NCC2287, even when a decrease in the levels of specific antibo-
dies is not observed [31]. In the ACA test carried out in our model, those ani-
mals belonging to the E. faecalis CECT7121/OVA group displayed the same de-
gree of dye extravasation as control S/OVA animals (Figure 4), evidencing va-
sodilatation and a vascular permeability increase caused by mast cells degranula-
tion. 
Taking into account the results obtained herein, together with those published 
demonstrating the preventive effect of E. faecalis CECT7121 on the development 
of allergy [23], it can be concluded that this bacterium as it was administered 
could decrease the anti-OVA IgG1/IgG2a ratios observed in the group of ani-
mals treated with the bacterium due to a rise in the levels of specific IgG2a, but it 
could not reduce IgE levels nor show differences in the ACA test, so it would not 
be appropriate for the treatment of allergic symptoms in the OVA allergy in-
duced model. These results reinforce the hypothesis that each probiotic strain 
can have a differential effect on both phases of the allergic response. 
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